Osimertinib Mesylate CAS 1421373-66-1 Raw Materials Powder

CAS: 1421373-66-1

MF: C29H37N7O5S

Specification​: 99% min Osimertinib Mesylate

Sample: Osimertinib Mesylate Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Osimertinib Mesylate Usage and Synthesis .

Osimertinib Mesylate Powder (AZD9291) is an oral drug that is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Osimertinib Mesylate CAS 1421373-66-1 is used to treat patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) T790M mutation or resistance to other EGFR inhibitors. EGFR inhibitor osimertinib. China Pharmaceutical Factory Osimertinib Mesylate Supplier Professional Pharmaceutical Ingredients.

AZD9291 is an oral drug that is a third-generation epidermal Growth factor receptor (EGFR) tyrosine kinase inhibitor. It was developed by AstraZeneca for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).

EGFR is a receptor tyrosine kinase that plays an important role in cell growth and division. EGFR mutations are among the most common mutations in NSCLC, accounting for approximately 30% of cases. These mutations can lead to over-activation of EGFR and promote cancer cell growth and division. AZD9291 blocks this over-activation by inhibiting EGFR tyrosine kinase activity, thereby inhibiting cancer cell growth and division.

Unlike other EGFR inhibitors, AZD9291 is able to inhibit some common EGFR mutations, such as T790M, which is a mutation that other EGFR inhibitors cannot inhibit. This makes AZD9291 a promising agent for the treatment of EGFR mutation-positive NSCLC.

Application/Function of Osimertinib Mesylate.

AZD9291 can be administered more conveniently as an oral drug, avoiding the inconvenience of intravenous injections. Its safety and tolerability have also been extensively studied and demonstrated. In clinical trials, AZD9291 has been shown to be an effective therapeutic agent that can prolong patient survival.

However, there are some side effects associated with AZD9291. The most common side effects are nausea, vomiting and diarrhea. It may also cause uncomfortable symptoms such as itchy skin, fatigue and headache. During treatment, doctors need to closely monitor the patient's condition and side effects and make adjustments as needed.

Overall, AZD9291 is a very promising drug for the treatment of EGFR mutation-positive NSCLC. Its unique mechanism and oral administration provide patients with better treatment options. Although it has some side effects, it can be used safely under the guidance of a physician, resulting in longer survival and better quality of life.

Production method of Osimertinib Mesylate.

Osimertinib mesylate (AZD9291) is the mesylate form of osimertinib, an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase (TKI) inhibitor.